{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:24:05Z","timestamp":1787142245710,"version":"build-2736575974"},"reference-count":22,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by persistent inflammation of the colonic mucosa, resulting from a complex interplay between epithelial barrier dysfunction, dysregulated immune responses, and alterations in the gut microbiota. Despite advances in therapeutic strategies, current treatments for UC remain suboptimal. Many conventional and biologic therapies are associated with systemic side effects due to non-specific distribution, which can limit their long-term use. Novel acting therapies are needed for ulcerative colitis. This study evaluated the efficacy of intracolonic Rifamycin SV in situ gelling formulation (CB-01-35) in a rat model of oxazolone-induced colitis. Methods: Acute colitis was induced in female Wistar rats using oxazolone. Animals were treated for three days with CB-01-35 (80 mg\/kg, intracolonic), Vehicle, Asacol, or dexamethasone. Clinical parameters, colon weight, macroscopic damage score (MDS), mucosal damage area, and histological score were assessed. Results: CB-01-35 significantly reduced MDS compared with Vehicle (p &lt; 0.05) and showed a trend toward reduced mucosal damage area (p = 0.06). Histological analysis confirmed significant improvement, with reduced leukocyte infiltration and epithelial damage. No significant effects were observed on body weight or colon weight. Comparator treatments showed limited or inconsistent efficacy. Conclusions: CB-01-35 demonstrated therapeutic activity in this preclinical model, supporting further investigation as a locally acting treatment for colitis. These findings represent an initial proof-of-concept and warrant confirmation in larger and mechanistic studies.<\/jats:p>","DOI":"10.3390\/jcm15166409","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:04:12Z","timestamp":1787137452000},"page":"6409","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intracolonic Treatment with a Rifamycin SV In Situ Gelling Formulation Ameliorates Macroscopic and Histological Damage in an Acute Rat Model of Oxazolone-Induced Colitis: A Proof-of-Concept Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Katia","family":"Mangano","sequence":"first","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95125 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8593-6179","authenticated-orcid":false,"given":"Gian Marco","family":"Leone","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95125 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-4597","authenticated-orcid":false,"given":"Roberto Di","family":"Marco","sequence":"additional","affiliation":[{"name":"Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Aiello","sequence":"additional","affiliation":[{"name":"Cosmo SpA, Via C. Colombo 1, 20045 Lainate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Quattrocchi","sequence":"additional","affiliation":[{"name":"Cosmo SpA, Via C. Colombo 1, 20045 Lainate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Longo","sequence":"additional","affiliation":[{"name":"Cosmo N.V., 7th Floor 91\/94 North Wall Quay, D01 H7V7 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pagani","sequence":"additional","affiliation":[{"name":"Cosmo SpA, Via C. Colombo 1, 20045 Lainate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Gerloni","sequence":"additional","affiliation":[{"name":"Cosmobiolabs, 6199 Cornerstone Court E., Suite 101, San Diego, CA 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-025-02345-1","article-title":"Ulcerative Colitis: Signaling Pathways, Therapeutic Targets and Interventional Strategies","volume":"11","author":"Jia","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10620-010-1334-y","article-title":"A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis","volume":"56","author":"Lamet","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/ecco-jcc\/jjac081","article-title":"Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: A Randomised, Controlled, Non-inferiority Trial","volume":"16","author":"Kruis","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pudipeddi, A., Ko, Y., Paramsothy, S., and Leong, R.W. (2022). Vedolizumab Has Longer Persistence than Infliximab as a First-Line Biological Agent but Not as a Second-Line Biological Agent in Moderate-to-Severe Ulcerative Colitis: Real-World Registry Data from the Persistence Australian National IBD Cohort (PANIC) Study. Ther. Adv. Gastroenterol., 15.","DOI":"10.1177\/17562848221080793"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fabisiak, A., Caban, M., Dudek, P., Strig\u00e1\u010d, A., Ma\u0142ecka-Wojciesko, E., and Talar-Wojnarowska, R. (2025). Advancements in Dual Biologic Therapy for Inflammatory Bowel Diseases: Efficacy, Safety, and Future Directions. Ther. Adv. Gastroenterol., 18.","DOI":"10.1177\/17562848241309871"},{"key":"ref_6","first-page":"21","article-title":"A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis","volume":"16","author":"Cohen","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/jpn3.70245","article-title":"Drugs in focus: Budesonide and its role in paediatric gastrointestinal disorders","volume":"82","author":"Aziz","year":"2026","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1007\/s10620-015-3868-5","article-title":"Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis","volume":"60","author":"Rubin","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gut.40.6.775","article-title":"Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis","volume":"40","author":"Marshall","year":"1997","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4939-3603-8_23","article-title":"Oxazolone-Induced Colitis as a Model of Th2 Immune Responses in the Intestinal Mucosa","volume":"1422","author":"Weigmann","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhang, L., Cao, N., Wang, Y., Wang, Y., Wu, C., Cheng, X., and Wang, C. (2019). Improvement of Oxazolone-Induced Ulcerative Colitis in Rats Using Andrographolide. Molecules, 25.","DOI":"10.3390\/molecules25010076"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Feng, J.J., Maddirala, N.R., Saint Fleur, A., Zhou, F., Yu, D., Wei, F., and Zhang, Y. (2025). Gut Microbiome and Immune System Crosstalk in Chronic Inflammatory Diseases: A Narrative Review of Mechanisms and Therapeutic Opportunities. Microorganisms, 13.","DOI":"10.3390\/microorganisms13112516"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hu, Y., Chen, Z., Xu, C., Kan, S., and Chen, D. (2022). Disturbances of the Gut Microbiota and Microbiota-Derived Metabolites in Inflammatory Bowel Disease. Nutrients, 14.","DOI":"10.3390\/nu14235140"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zdybel, K., \u015aliwka, A., Polak-Berecka, M., Polak, P., and Wa\u015bko, A. (2025). Postbiotics Formulation and Therapeutic Effect in Inflammation: A Systematic Review. Nutrients, 17.","DOI":"10.3390\/nu17132187"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijantimicag.2013.04.020","article-title":"Anti-Inflammatory and Immunomodulatory Activities of Rifamycin SV","volume":"42","author":"Rosette","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00054725-200201000-00004","article-title":"Pouchitis in a Rat Model of Ileal J Pouch\u2013Anal Anastomosis","volume":"8","author":"Shebani","year":"2002","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dmpk.2019.01.002","article-title":"Rifamycin SV Exhibits Strong Anti-Inflammatory in Vitro Activity through Pregnane X Receptor Stimulation and NF\u03baB Inhibition","volume":"34","author":"Rosette","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1007\/s13346-025-01808-w","article-title":"A Rifamycin SV in Situ Gelling Formulation for the Treatment of Pouchitis","volume":"15","author":"Mangano","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1003232","DOI":"10.37349\/ei.2025.1003232","article-title":"Advancements in Therapeutic Strategies and Drug Development for Inflammatory Bowel Diseases","volume":"5","author":"Zhou","year":"2025","journal-title":"Explor. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/jtm.12168","article-title":"Targeting of Rifamycin SV to the Colon for Treatment of Travelers\u2019 Diarrhea: A Randomized, Double-Blind, Vehicle-Controlled Phase 3 Study","volume":"21","author":"DuPont","year":"2014","journal-title":"J. Travel Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11302-017-9591-2","article-title":"Anti-Inflammatory Effect of a Novel Locally Acting A2A Receptor Agonist in a Rat Model of Oxazolone-Induced Colitis","volume":"14","author":"Antonioli","year":"2018","journal-title":"Purinergic Signal."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.110.170225","article-title":"Therapeutic role of rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X receptor activation","volume":"335","author":"Cheng","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6409\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:26:25Z","timestamp":1787138785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":22,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166409"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166409","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}